{"id":"https://openalex.org/W2904320752","doi":"https://doi.org/10.1002/cncr.31889","title":"Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1\u2010based therapy","display_name":"Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1\u2010based therapy","publication_year":2018,"publication_date":"2018-12-06","ids":{"openalex":"https://openalex.org/W2904320752","doi":"https://doi.org/10.1002/cncr.31889","mag":"2904320752","pmid":"https://pubmed.ncbi.nlm.nih.gov/30521084","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8074192"},"language":"en","primary_location":{"id":"doi:10.1002/cncr.31889","doi":"https://doi.org/10.1002/cncr.31889","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.31889","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.31889","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.31889","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090268681","display_name":"Karim R. Saab","orcid":"https://orcid.org/0009-0003-3678-9007","observed_orcids":["https://orcid.org/0009-0003-3678-9007"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karim R. Saab","raw_affiliation_strings":["Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York","Department of Medicine, Weill Cornell Medical College, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York","institution_ids":["https://openalex.org/I1334819555"]},{"raw_affiliation_string":"Department of Medicine, Weill Cornell Medical College, New York, New York","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083431383","display_name":"Meghan J. Mooradian","orcid":"https://orcid.org/0000-0002-8289-8015","observed_orcids":["https://orcid.org/0000-0002-8289-8015"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meghan J. Mooradian","raw_affiliation_strings":["Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089223773","display_name":"Daniel Y. Wang","orcid":"https://orcid.org/0000-0002-3341-8652","observed_orcids":["https://orcid.org/0000-0002-3341-8652"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Y. Wang","raw_affiliation_strings":["Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021765564","display_name":"Jeewon Chon","orcid":"https://orcid.org/0000-0001-9978-6127","observed_orcids":["https://orcid.org/0000-0001-9978-6127"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeewon Chon","raw_affiliation_strings":["Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065473791","display_name":"Cathy Yi Xia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118383","display_name":"Melanoma Institute Australia","ror":"https://ror.org/02jxrhq31","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I4210118383"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Cathy Y. Xia","raw_affiliation_strings":["Department of Medicine, Melanoma Institute Australia, Sydney, New South Wales, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Melanoma Institute Australia, Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I4210118383"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081603469","display_name":"Angelica Bialczak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Angelica Bialczak","raw_affiliation_strings":["Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022927802","display_name":"Kelly T. Abbate","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kelly T. Abbate","raw_affiliation_strings":["Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022520811","display_name":"Alexander Maxwell Menzies","orcid":"https://orcid.org/0000-0001-5183-7562","observed_orcids":["https://orcid.org/0000-0001-5183-7562"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I4210118383","display_name":"Melanoma Institute Australia","ror":"https://ror.org/02jxrhq31","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I4210118383"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Alexander M. Menzies","raw_affiliation_strings":["Department of Medicine, Melanoma Institute Australia, Sydney, New South Wales, Australia","The University of Sydney, Sydney, New South Wales, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Melanoma Institute Australia, Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I4210118383"]},{"raw_affiliation_string":"The University of Sydney, Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I129604602"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025067315","display_name":"Douglas Buckner Johnson","orcid":"https://orcid.org/0000-0002-6390-773X","observed_orcids":["https://orcid.org/0000-0002-6390-773X"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas B. Johnson","raw_affiliation_strings":["Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"],"raw_orcid":"https://orcid.org/0000-0002-6390-773X","affiliations":[{"raw_affiliation_string":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008479799","display_name":"Ryan Joseph Sullivan","orcid":"https://orcid.org/0000-0001-5344-6645","observed_orcids":["https://orcid.org/0000-0001-5344-6645"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan J. Sullivan","raw_affiliation_strings":["Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5040291209","display_name":"Alexander Noor Shoushtari","orcid":"https://orcid.org/0000-0002-8065-4412","observed_orcids":["https://orcid.org/0000-0002-8065-4412"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Alexander N. Shoushtari","raw_affiliation_strings":["Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York","Department of Medicine, Weill Cornell Medical College, New York, New York"],"raw_orcid":"https://orcid.org/0000-0002-8065-4412","affiliations":[{"raw_affiliation_string":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York","institution_ids":["https://openalex.org/I1334819555"]},{"raw_affiliation_string":"Department of Medicine, Weill Cornell Medical College, New York, New York","institution_ids":["https://openalex.org/I4387153466"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5040291209"],"corresponding_institution_ids":["https://openalex.org/I1334819555","https://openalex.org/I4387153466"],"apc_list":{"value":4790,"currency":"USD","value_usd":4790},"apc_paid":null,"fwci":2.7547,"has_fulltext":true,"cited_by_count":51,"citation_normalized_percentile":{"value":0.92114743,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"125","issue":"6","first_page":"884","last_page":"891"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/braf-mek-inhibition","display_name":"BRAF/MEK inhibition","score":0.8180000185966492},{"id":"https://openalex.org/keywords/braf-v600-mutant-melanoma","display_name":"BRAF V600-mutant melanoma","score":0.9350000023841858},{"id":"https://openalex.org/keywords/dabrafenib","display_name":"dabrafenib","score":0.9449999928474426},{"id":"https://openalex.org/keywords/trametinib","display_name":"trametinib","score":1.0},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.8309999704360962},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.5929999947547913},{"id":"https://openalex.org/keywords/fever","display_name":"fever","score":0.781000018119812},{"id":"https://openalex.org/keywords/hospitalization","display_name":"hospitalization","score":0.6819999814033508},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8579999804496765}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9159926176071167},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.8592734932899475},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.8198095560073853},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.7135040760040283},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.7037938833236694},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.6248458623886108},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5865413546562195},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5432838201522827},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.46583524346351624},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46475186944007874},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.23804661631584167},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.18107503652572632},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.16992855072021484},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.1292242407798767},{"id":"https://openalex.org/C11960822","wikidata":"https://www.wikidata.org/wiki/Q242736","display_name":"Phosphorylation","level":2,"score":0.07830879092216492},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001315","descriptor_name":"Australia","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010091","descriptor_name":"Oximes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D010091","descriptor_name":"Oximes","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011744","descriptor_name":"Pyrimidinones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011744","descriptor_name":"Pyrimidinones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D062606","descriptor_name":"Tertiary Care Centers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/cncr.31889","doi":"https://doi.org/10.1002/cncr.31889","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.31889","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.31889","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},{"id":"pmid:30521084","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30521084","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8074192","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8074192","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Cancer","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1002/cncr.31889","doi":"https://doi.org/10.1002/cncr.31889","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.31889","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.31889","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[{"id":"https://openalex.org/G9000083166","display_name":"Vanderbilt Clinical Oncology Research Career Development Award","funder_award_id":"K12CA090625","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000856728","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA008748","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2904320752.pdf","grobid_xml":"https://content.openalex.org/works/W2904320752.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W1965370740","https://openalex.org/W1967551644","https://openalex.org/W2010121426","https://openalex.org/W2040956995","https://openalex.org/W2117138659","https://openalex.org/W2121545342","https://openalex.org/W2128035403","https://openalex.org/W2150669821","https://openalex.org/W2152897456","https://openalex.org/W2160766792","https://openalex.org/W2299181842","https://openalex.org/W2491982852","https://openalex.org/W2549612601","https://openalex.org/W2560367415","https://openalex.org/W2605630889","https://openalex.org/W2608329604","https://openalex.org/W2620651944","https://openalex.org/W2745671375","https://openalex.org/W2749408522","https://openalex.org/W2753432434","https://openalex.org/W2762161610","https://openalex.org/W2790692623","https://openalex.org/W2793817570","https://openalex.org/W2800368813","https://openalex.org/W2809417568","https://openalex.org/W2887127301"],"related_works":["https://openalex.org/W2890461491","https://openalex.org/W2948884915","https://openalex.org/W4281680831","https://openalex.org/W4284669148","https://openalex.org/W2891411265","https://openalex.org/W2946610417","https://openalex.org/W1965480120","https://openalex.org/W2944196574","https://openalex.org/W2025069507","https://openalex.org/W2092383314"],"abstract_inverted_index":{"BACKGROUND:":[0],"Combined":[1],"BRAF":[2,14,47],"and":[3,28,69,87,94,149,188,209,239,260,278],"MEK":[4],"inhibition":[5,253],"(BRAF-MEK)":[6],"is":[7],"a":[8,76,123,127,261],"standard":[9],"therapy":[10,57,235,256,277],"for":[11,266],"patients":[12,117,142,154,198,250],"with":[13,46],"V600-mutant":[15,48],"melanoma,":[16],"but":[17],"to":[18,90,175,222,283],"the":[19,22,36,66,104,107,133,145,176,204,216,230,240,273],"authors'":[20],"knowledge,":[21],"tolerance,":[23],"adverse":[24],"event":[25],"(AE)":[26],"profile,":[27],"efficacy":[29],"have":[30],"not":[31,212],"been":[32],"well":[33],"defined":[34,74],"in":[35,65,197,286],"post-programmed":[37],"cell":[38],"death":[39],"protein":[40],"1":[41],"(PD-1)":[42],"setting.":[43],"METHODS:":[44],"Patients":[45],"melanoma":[49],"who":[50,210],"received":[51,122,144],"combined":[52],"BRAF-MEK":[53,110,124,200,234,252],"after":[54,132,203,254],"prior":[55],"PD-1-based":[56,137],"were":[58,92,118,194,211],"assembled":[59],"from":[60,103],"4":[61],"tertiary":[62],"care":[63],"centers":[64],"United":[67],"States":[68],"Australia.":[70],"Dose":[71,192],"modification":[72,179],"was":[73,98,180,236,243],"as":[75,120],"treatment":[77],"break,":[78],"dose":[79,135,170,178,206,217,258],"reduction,":[80],"or":[81,162],"intermittent":[82],"dosing.":[83],"Rates":[84],"of":[85,106,109,115,129,136,141,147,153,207,249],"hospitalization":[86,265],"discontinuation":[88],"due":[89],"AEs":[91],"collected,":[93],"overall":[95],"survival":[96],"(OS)":[97],"calculated":[99],"using":[100],"Kaplan-Meier":[101],"methods":[102],"time":[105,174,232,275],"initiation":[108],"therapy.":[111,138],"RESULTS:":[112],"A":[113],"total":[114],"78":[116],"identified":[119],"having":[121],"regimen":[125],"at":[126],"median":[128,173,231,241,274],"34":[130],"days":[131,187,202],"last":[134,205],"The":[139,172,247],"majority":[140,248],"(86%)":[143],"combination":[146],"dabrafenib":[148],"trametinib.":[150],"Approximately":[151],"80%":[152],"had":[155,168],"American":[156],"Joint":[157],"Committee":[158],"on":[159],"Cancer":[160],"M1c":[161],"M1d":[163],"disease.":[164],"Sixty-five":[165],"regimens":[166],"(83%)":[167],"\u22651":[169],"modification.":[171],"first":[177],"14":[181],"days;":[182],"86%":[183],"occurred":[184],"within":[185],"90":[186],"71%":[189],"involved":[190],"pyrexia.":[191],"modifications":[193],"more":[195],"common":[196],"receiving":[199,213,233,251,276],"<90":[201],"PD-1":[208,255],"steroids.":[214],"Of":[215],"modifications,":[218],"25":[219],"(31%)":[220],"led":[221],"an":[223],"AE-related":[224],"hospitalization.":[225],"Among":[226],"55":[227],"BRAF-naive":[228],"patients,":[229],"5.8":[237],"months":[238],"OS":[242,279],"15.6":[244],"months.":[245],"CONCLUSIONS:":[246],"require":[257,264],"interruptions,":[259],"significant":[262],"minority":[263],"AEs.":[267],"In":[268],"this":[269],"higher":[270],"risk":[271],"population,":[272],"may":[280],"be":[281],"inferior":[282],"those":[284],"presented":[285],"published":[287],"phase":[288],"3":[289],"trials.":[290]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":8}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-12-22T00:00:00"}